Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



MS News: European Research Program To Monitor MS Through Wearable Device, Smartphones As EU Approves Biogen, AbbVie MS Drugs

Multiple Sclerosis sufferer and right-to-die campaigner Debbie Purdy speaks to the press on college green on February 25, 2010 in London, England. 
(Photo : Dan Kitwood/Getty Images)

Over 2.3 million people are affected by multiple sclerosis (MS) worldwide. Fortunately, a new research program called the RADAR-CNS (Remote assessment of disease and relapse Central Nervous System) project targets to improve patients' quality of life with new drugs approved from Biogen and AbbVie.

The prevalence of multiple sclerosis in the United States can only be estimated since the U.S. Centers for Disease Control and Prevention (CDC) does not require American doctors to report cases. But in the U.K., the neurological condition affects about 100,000 people and most are diagnosed between the ages of 20-40, Multiple Sclerosis Society reveals.

What Is Multiple Sclerosis?

Multiple sclerosis is an unpredictable yet chronic disease of the central nervous system (CNS) that covers the brain, spinal cord and optic nerves. It is an auto-immune disease, where the immune system incorrectly attacks healthy CNS tissue, National Multiple Sclerosis Society defines.

Multiple Sclerosis Signs And Symptoms

The cause of multiple sclerosis remains unknown but it is linked to genetic and environmental factors. MS signs and symptoms may vary but it include prolonged double vision, partial or complete loss of vision, numbness or weakness in one or more limbs, tingling or pain in parts of your body, unsteady gait or tremor, slurred speech, fatigue and dizziness, Fox 8 reports.

New European Research Program

The Innovative Medicines Initiative (IMI), which includes 24 member organizations across Europe and the U.S., has funded a new European research program known as the RADAR-CNS project. According to Multiple Sclerosis News Today, the program focuses on developing ways to monitor three main central nervous system diseases: multiple sclerosis, depressive disorder and epilepsy.

Launched on Apr. 26, the RADAR-CNS program is led by Kings College London and Janssen Pharmaceutica NV. By using smartphones and wearable device technology, the program enables a continuous remote assessment of patients and with multiple sclerosis, depressive disorder and epilepsy.

This latest multiple sclerosis monitoring scheme also provides a complete picture of real-time health status with levels of detail once unachievable. It also has the potential to initiate treatment before someone's health deteriorates by preventing relapses or arresting progression before a patient's need for treatment.

Biogen And AbbVie Multiple Sclerosis Injection

In addition to the latest multiple sclerosis monitoring program, EU regulators has finally approved a monthly, self-administered and under-the-skin injection from Biogen and AbbVie. The European Medicines Agency said on Apr. 29 that experts had endorsed Zinbryta, or daclizumab, for the treatment of relapsing

Story Source: The above story is based on materials provided by PARENTHERALD
Note: Materials may be edited for content and length

Go to Newer News Go to Older News